Electrophysiological effects of carvedilol on rabbit heart pacemaker cells

International Heart Journal

Volumn 48, Issue 3, 2007, Pages 347-357

  Yokoyama, Ayumi ^a   Sato, Nobuyuki ^a   Kawamura, Yuichiro ^a   Hasebe, Naoyuki ^a   Kikuchi, Kenjiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

blocking agent; Atrioventricular (AV) node; Ca2+ current (ICa); Delayed rectifier K+ current(Ik); Hyperpolarization activated inward current(If); Sinoatrial (SA) node; Whole cell patch clamp

Indexed keywords

CARVEDILOL;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; CALCIUM CURRENT; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; HEART ATRIOVENTRICULAR NODE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HYPERPOLARIZATION; NONHUMAN; PHARMACOLOGICAL BLOCKING; POTASSIUM CURRENT; PRIORITY JOURNAL; RABBIT; SINUS NODE; SUPRAVENTRICULAR TACHYCARDIA; VOLTAGE CLAMP;

ACTION POTENTIALS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATRIOVENTRICULAR NODE; CALCIUM CHANNELS, L-TYPE; CARBAZOLES; CARDIAC PACING, ARTIFICIAL; DISEASE MODELS, ANIMAL; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; PROPANOLAMINES; RABBITS; SINOATRIAL NODE; TACHYCARDIA, SUPRAVENTRICULAR;

EID: 34547527104     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.48.347     Document Type: Article

References (32)

1. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990; 38: S82-8. (Review)
2. Yaoita H, Sakabe A, Maehara Y, Maruyama Y. Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation 2002; 105:975-80.
3. Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR Jr, Yue TL. A comparison of cavedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol 2000; 36:277-81.
4. 2+ current in rabbit ventricular myocytes. Eur J Pharmacol 1999; 376: 189-201.
5. Okafor CC, Perreault-Micale C, Hajjar RJ, et al. Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. BMC Physiol 2003; 3: 6.
6. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997; 29: 1060-6.
7. Palazzuoli A, Bruni F, Puccetti L, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002; 4: 765-70.
8. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure: Study Group. N Engl J Med 1996; 334: 1349-55.
9. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996; 94:2793-9.
10. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996; 94: 2800-6.
11. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA investigators. Circulation 1996; 94: 2807-16.
12. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-9.
13. Basu S, Senior R, Raval U, van der Does R, Bruckner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation 1997; 96: 183-91.
14. Senior R, Muller-Beckmann B, DasGupta P, van der Does R, Lahiri A. Effects of carvedilol on ventricular arrhythmias. J Cardiovasc Pharmacol 1992; 19: S117-21.
15. Brunvand H, Frlyland I, Hexeberg E, Rynning SE, Berge RK, Grong K. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. Eur J Pharmacol 1996; 314: 99-107.
16. Hoher M, Friedrich M, Sommer T, et al. Effects of carvedilol on left ventricular function and arrhythmias during repeated short-time myocardial ischemia in experimental pigs. Z Kardiol 1989; 78 (suppl): 7-15.
17. Bril A, Tomasi V, Laville MP. Antiarrhythmic effects of carvedilol in rat isolated heart subjected to ischemia and reperfusion. Pharmacol Commun 1995; 5: 281-300.
18. Karle CA, Kreye VA, Thomas D, et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 2001; 49: 361-70.
19. Ka, in pacemaker activity of rabbit isolated sino-atrial node cells. Cardiovase Res 2002; 53: 68-79.
20. Howarth FC, Levi AJ, Hancox JC. Characteristics of the delayed rectifier K current compared in myocytes isolated from the atrioventricular node and ventricle of the rabbit heart. Pflugers Arch 1996, 431: 713-22.
21. + current in rabbit sinoatrial and atrioventricular node cells. Eur J Pharmacol 2000, 404: 281-8.
22. Tohse N. Analysis of membrane current system involved in the inotropic effects mediated by α-adrenoceptors in the heart. Hokkaido Igaku-Zasshi 1988; 63: 754-71. (Japanese).
23. Satoh H. Different actions between pindolol and propranolol on the ionic currents in spontaneously beating rabbit sino-atrial node cells. J Cardiovasc Pharmacol 1995; 25: 967-72.
24. Dukes ID, Vaughan Williams EM. Electrophysiological effects of α-adenoceptor antagonists in rabbit sino-atrial node, cardiac Purkinje cells and papillary muscles. Br J Pharmacol 1984; 83: 419-26.
25. McPhillips JJ, Schwemer GT, Scott DI, Zinny M, Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. Drugs 1988; 36 (suppl): 82-91.
26. Morgan T, Anderson A, Cripps J, Adam W. Pharmacokinetics of carvedilol in older and younger patients. J Hum Hypertens 1990; 4: 709-15.
27. Cheung DW. Electrical activity of the pulmonary vein and its interaction wilh the right atrium in the guinea-pig. J Physiol, 1981; 314:445-56.
28. Ehrlich JR, Cha TJ, Zhang L, et al. Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties. J Physiol 2003; 551: 801-13.
29. Perez-Lugones A, McMahon JT, Ratliff NB, et al. Evidence of specialized conduction cells in human pulmonary veins of patients with atrial fibrillation. J Cardiovasc Eletrophysiol 2003; 14: 803-9.
30. Munk AA, Adjemian RA, Zhao J, Ogbaghebriel A. Shrier A. Electrophysiological properties of morphologically distinct cells isolated from the rabbit atrioventricular node. J Physiol 1996; 493: 801-18.
31. K,s in rabbit sinoatrial node cells. J Physiol 2001; 535: 703-14.
32. Boyett MR, Honjo H, Kodama I. The sinoatrial node, a heterogeneous pacemaker structure. Cardiovasc Res 2000; 47: 658-87. (Review)